Glycogen storage disease type1 and diabetes: Learning by comparing and contrasting the two disorders

Diabetes and Metabolism

Volumn 39, Issue 5, 2013, Pages 377-387

  Rajas, F ^a,b,c   Labrune, P ^d,e   Mithieux, G ^a,b,c  

^a INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Glucose and lipid metabolism; Glycogenic hepatopathy; Hepatocellular adenomas and carcinomas; Liver steatosis; Nephropathy

Indexed keywords

BINDING PROTEIN; CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCAGON; GLUCOSE 6 PHOSPHATASE; METFORMIN; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

COMPARATIVE STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG TARGETING; ENERGY BALANCE; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOGEN STORAGE DISEASE TYPE 1; HEPATOMEGALY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIPID METABOLISM; LIVER TUMOR; MEDICAL SPECIALIST; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION;

ADÉNOMES ET CARCINOMES HÉPATOCELLULAIRES; GLUCOSE AND LIPID METABOLISM; GLYCOGENIC HEPATOPATHY; HEPATOCELLULAR ADENOMAS AND CARCINOMAS; HÉPATOMÉGALIE; LIVER STEATOSIS; MÉTABOLISME GLUCIDIQUE ET LIPIDIQUE; NEPHROPATHY; NÉPHROPATHIE; STÉATOSE HÉPATIQUE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FASTING; FATTY LIVER; FEMALE; GLYCOGEN STORAGE DISEASE TYPE I; HEPATOCYTES; HUMANS; HYPOGLYCEMIA; KIDNEY DISEASES; MALE; POSTPRANDIAL PERIOD;

EID: 84885932915     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.03.002     Document Type: Review

References (126)

1. Chou J.Y., Jun H.S., Mansfield B.C. Glycogen storage disease type I and G6Pase-beta deficiency: etiology and therapy. Nat Rev Endocrinol 2010, 6:676-688.
2. Froissart R., Piraud M., Boudjemline A.M., Vianey-Saban C., Petit F., Hubert-Buron A., et al. Glucose-6-phosphatase deficiency. Orphanet J Rare Dis 2011, 6:27.
3. Shieh J.J., Terzioglu M., Hiraiwa H., Marsh J., Pan C.J., Chen L.Y., et al. The molecular basis of glycogen storage disease type 1a: structure and function analysis of mutations in glucose-6-phosphatase. J Biol Chem 2002, 277:5047-5053.
4. Rajas F., Bruni N., Montano S., Zitoun C., Mithieux G. The glucose-6 phosphatase gene is expressed in human and rat small intestine: regulation of expression in fasted and diabetic rats. Gastroenterology 1999, 117:132-139.
5. Rajas F., Jourdan-Pineau H., Stefanutti A., Mrad E.A., Iynedjian P.B., Mithieux G. Immunocytochemical localization of glucose 6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase in gluconeogenic tissues reveals unsuspected metabolic zonation. Histochem Cell Biol 2007, 127:555-565.
6. Bruni N., Rajas F., Montano S., Chevalier-Porst F., Maire I., Mithieux G. Enzymatic characterization of four new mutations in the glucose-6 phosphatase (G6PC) gene which cause glycogen storage disease type 1a. Ann Hum Genet 1999, 63:141-146.
7. Chevalier-Porst F., Bozon D., Bonardot A.M., Bruni N., Mithieux G., Mathieu M., et al. Mutation analysis in 24 French patients with glycogen storage disease type 1a. J Med Genet 1996, 33:358-360.
8. Chou J.Y., Mansfield B.C. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 2008, 29:921-930.
9. Moses S. Historical highlights and unsolved problems in glycogen storage disease type 1. Eur J Pediatr 2002, 161:S2-S9.
10. Rake J.P., Visser G., Labrune P., Leonard J.V., Ullrich K., Smit G.P. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002, 161(Suppl 1):S20-S34.
11. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2011, 414:799-806.
12. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787-794.
13. Sala P.C., Torrinhas R.S., Heymsfield S.B., Waitzberg D.L. Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction. Obes Surg 2012, 22:167-176.
14. Herzig S. Liver: a target of late diabetic complications. Exp Clin Endocrinol Diabetes 2012, 120:202-204.
15. Hsieh P.S., Hsieh Y.J. Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol 2011, 17:5240-5245.
16. Lin H.V., Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab 2011, 14:9-19.
17. Mithieux G. A novel function of intestinal gluconeogenesis: central signaling in glucose and energy homeostasis. Nutrition 2009, 25:881-884.
18. Mithieux G., Andreelli F., Magnan C. Intestinal gluconeogenesis: key signal of central control of energy and glucose homeostasis. Curr Opin Clin Nutr Metab Care 2009, 12:419-423.
19. Mutel E., Gautier-Stein A., Abdul-Wahed A., Amigo-Correig M., Zitoun C., Stefanutti A., et al. Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 2011, 60:3121-3131.
20. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88:787-835.
21. Rizza R.A. Pathogenesis of fasting and postprandial hyperglycaemia in type 2 diabetes: implications for therapy. Diabetes 2010, 59:2697-2707.
22. Campbell P.J., Mandarino L.J., Gerich J.E. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 1988, 37:15-21.
23. Jeng C.Y., Sheu W.H., Fuh M.M., Chen Y.D., Reaven G.M. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 1994, 43:1440-1444.
24. Tayek J.A., Katz J. Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study. Am J Physiol 1996, 270:E709-E717.
25. Nurjhan N., Consoli A., Gerich J. Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus. J Clin Invest 1992, 89:169-175.
26. Mevorach M., Giacca A., Aharon Y., Hawkins M., Shamoon H., Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 1998, 102:744-753.
27. Dunning B.E., Gerich J.E. The role of alpha-cell dysregulation in fasting and postprandial hyperglycaemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007, 28:253-283.
28. Bansal P., Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab 2008, 295:E751-E761.
29. Cryer P.E. Minireview: glucagon in the pathogenesis of hypoglycaemia and hyperglycaemia in diabetes. Endocrinology 2011, 153:1039-1048.
30. Unger R.H., Cherrington A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012, 122:4-12.
31. Mithieux G. Brain, liver, intestine: a triumvirate to coordinate insulin sensitivity of endogenous glucose production. Diabetes Metab 2010, 36(Suppl 3):S50-S53.
32. Trinh K.Y., O'Doherty R.M., Anderson P., Lange A.J., Newgard C.B. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem 1998, 273:31615-31620.
33. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
34. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
35. Postic C., Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008, 34:643-648.
36. Denechaud P.D., Bossard P., Lobaccaro J.M., Millatt L., Staels B., Girard J., et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest 2008, 118:956-964.
37. Bandsma R.H., Prinsen B.H., van Der Velden Mde S., Rake J.P., Boer T., Smit G.P., et al. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 2008, 63:702-707.
38. Bandsma R.H., Wiegman C.H., Herling A.W., Burger H.J., ter Harmsel A., Meijer A.J., et al. Acute inhibition of glucose-6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes 2001, 50:2591-2597.
39. Grefhorst A., Schreurs M., Oosterveer M.H., Cortes V.A., Havinga R., Herling A.W., et al. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor alpha (LXRalpha) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1. Biochem J 2010, 432:249-254.
40. Gariani K., Philippe J., Jornayvaz F.R. Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. Diabetes Metab 2013, 39:16-26.
41. Shimomura I., Bashmakov Y., Ikemoto S., Horton J.D., Brown M.S., Goldstein J.L. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 1999, 96:13656-13661.
42. Shimomura I., Matsuda M., Hammer R.E., Bashmakov Y., Brown M.S., Goldstein J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000, 6:77-86.
43. Li S., Brown M.S., Goldstein J.L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010, 107:3441-3446.
44. Cnop M., Foufelle F., Velloso L.A. Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 2011, 18:59-68.
45. Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010, 12(Suppl 2):83-92.
46. Regnell S.E., Lernmark A. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011, 8:454-467.
47. Farese R.V., Zechner R., Newgard C.B., Walther T.C. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012, 15:570-573.
48. Sun Z., Lazar M.A. Dissociating fatty liver and diabetes. Trends Endocrinol Metab 2013, 24:4-12.
49. Kato T., Shimano H., Yamamoto T., Ishikawa M., Kumadaki S., Matsuzaka T., et al. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 2008, 57:2382-2392.
50. Martins A.R., Nachbar R.T., Gorjao R., Vinolo M.A., Festuccia W.T., Lambertucci R.H., et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis 2012, 11:30.
51. Matsuzaka T., Shimano H., Yahagi N., Kato T., Atsumi A., Yamamoto T., et al. Crucial role of a long-chain fatty acid elongase. Elovl6, in obesity-induced insulin resistance. Nat Med 2007, 13:1193-1202.
52. Thorn K., Hovsepyan M., Bergsten P. Reduced levels of SCD1 accentuate palmitate-induced stress in insulin-producing beta-cells. Lipids Health Dis 2010, 9:108.
53. Henique C., Mansouri A., Fumey G., Lenoir V., Girard J., Bouillaud F., et al. Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J Biol Chem 2010, 285:36818-36827.
54. Listenberger L.L., Han X., Lewis S.E., Cases S., Farese R.V., Ory D.S., et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003, 100:3077-3082.
55. Ricchi M., Odoardi M.R., Carulli L., Anzivino C., Ballestri S., Pinetti A., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009, 24:830-840.
56. Tardif N., Salles J., Landrier J.F., Mothe-Satney I., Guillet C., Boue-Vaysse C., et al. Oleate-enriched diet improves insulin sensitivity and restores muscle protein synthesis in old rats. Clin Nutr 2011, 30:799-806.
57. Benhamed F., Denechaud P.D., Lemoine M., Robichon C., Moldes M., Bertrand-Michel J., et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 2012, 122:2176-2194.
58. Feng D., Liu T., Sun Z., Bugge A., Mullican S.E., Alenghat T., et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011, 331:1315-1319.
59. Sun Z., Miller R.A., Patel R.T., Chen J., Dhir R., Wang H., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med 2012, 18:934-942.
60. Calderaro J., Labrune P., Morcrette G., Rebouissou S., Franco D., Prevot S., et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol 2013, 58:350-357.
61. Wittenstein B., Klein M., Finckh B., Ullrich K., Kohlschutter A. Radical trapping in glycogen storage disease 1a. Eur J Pediatr 2002, 161(Suppl. 1):S70-S74.
62. Dragani T.A. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2009, 52:252-257.
63. Lee P. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002, 161:S46-S49.
64. Laumonier H., Bioulac-Sage P., Laurent C., Zucman-Rossi J., Balabaud C., Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008, 48:808-818.
65. Mutel E., Abdul-Wahed A., Ramamonjisoa N., Stefanutti A., Houberdon I., Cavassila S., et al. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. J Hepatol 2011, 54:529-537.
66. Franco L.M., Krishnamurthy V., Bali D., Weinstein D.A., Arn P., Clary B., et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005, 28:153-162.
67. Wang D.Q., Fiske L.M., Carreras C.T., Weinstein D.A. Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr 2011, 159:442-446.
68. Rake J.P., Visser G., Labrune P., Leonard J.V., Ullrich K., Smit G.P. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002, 161(Suppl 1):S112-S119.
69. Bost F., Sahra I.B., Le Marchand-Brustel Y., Tanti J.F. Metformin and cancer therapy. Curr Opin Oncol 2012, 24:103-108.
70. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
71. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., El-Serag H.B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54:533-539.
72. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
73. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
74. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115:5651-5661.
75. Gao C., Yao S.K. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma?. Hepatobiliary Pancreat Dis Int 2009, 8:465-473.
76. Ertle J., Dechene A., Sowa J.P., Penndorf V., Herzer K., Kaiser G., et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011, 128:2436-2443.
77. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
78. Bechmann L.P., Hannivoort R.A., Gerken G., Hotamisligil G.S., Trauner M., Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012, 56:952-964.
79. Hirsch H.A., Iliopoulos D., Joshi A., Zhang Y., Jaeger S.A., Bulyk M., et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010, 17:348-361.
80. Stefan N., Haring H.U. The metabolically benign and malignant fatty liver. Diabetes 2011, 60:2011-2017.
81. Miller A.M., Wang H., Bertola A., Park O., Horiguchi N., Ki S.H., et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011, 54:846-856.
82. Jiang R., Tan Z., Deng L., Chen Y., Xia Y., Gao Y., et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2012, 54:900-909.
83. Nault J.C., Zucman-Rossi J. Building a bridge between obesity, inflammation and liver carcinogenesis. J Hepatol 2010, 53:777-779.
84. Aghajan M., Li N., Karin M. Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. J Gastroenterol Hepatol 2012, 27(Suppl 2):10-14.
85. Chen Y., Klionsky D.J. The regulation of autophagy - unanswered questions. J Cell Sci 2011, 124:161-170.
86. Komatsu M. Liver autophagy: physiology and pathology. J Biochem 2012, 152:5-15.
87. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820.
88. Takamura A., Komatsu M., Hara T., Sakamoto A., Kishi C., Waguri S., et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011, 25:795-800.
89. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010, 30:750-758.
90. Lee M.S., Hsu C.C., Wahlqvist M.L., Tsai H.N., Chang Y.H., Huang Y.C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20.
91. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
92. Weinstein D.A., Correia C.E., Conlon T., Specht A., Verstegen J., Onclin-Verstegen K., et al. Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum Gene Ther 2010, 21:903-910.
93. Jung C., Gerdes N., Fritzenwanger M., Figulla H.R. Circulating levels of interleukin-1 family cytokines in overweight adolescents. Mediators Inflamm 2010, 2010:958403.
94. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980.
95. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
96. Torbenson M., Chen Y.Y., Brunt E., Cummings O.W., Gottfried M., Jakate S., et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006, 30:508-513.
97. van den Brand M., Elving L.D., Drenth J.P., van Krieken J.H. Glycogenic hepatopathy: a rare cause of elevated serum transaminases in diabetes mellitus. Neth J Med 2009, 67:394-396.
98. Sweetser S., Kraichely R.E. The bright liver of glycogenic hepatopathy. Hepatology 2010, 51:711-712.
99. Murata F., Horie I., Ando T., Isomoto E., Hayashi H., Akazawa S., et al. A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI. Endocr J 2012, 59:669-676.
100. Mundy H.R., Lee P.J. Glycogenosis type I and diabetes mellitus: a common mechanism for renal dysfunction?. Med Hypotheses 2002, 59:110-114.
101. Yiu W.H., Pan C.J., Ruef R.A., Peng W.T., Starost M.F., Mansfield B.C., et al. Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int 2008, 73:716-723.
102. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-[beta] pathway. Kidney Int 2006, 70:1914-1919.
103. Strippoli G.F., Craig M.C., Schena F.P., Craig J.C. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006, 17:S153-S155.
104. Martens D.H., Rake J.P., Navis G., Fidler V., van Dael C.M., Smit G.P. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol 2009, 4:1741-1746.
105. Melis D., Parenti G., Gatti R., Casa R.D., Parini R., Riva E., et al. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol (Oxf) 2005, 63:19-25.
106. Yiu W.H., Mead P.A., Jun H.S., Mansfield B.C., Chou J.Y. Oxidative stress mediates nephropathy in type Ia glycogen storage disease. Lab Invest 2010, 90:620-629.
107. Piwkowska A., Rogacka D., Jankowski M., Dominiczak M.H., Stepinski J.K., Angielski S. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem Biophys Res Commun 2010, 393:268-273.
108. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012, 122:253-270.
109. Guijarro C., Kasiske B.L., Kim Y., O'Donnell M.P., Lee H.S., Keane W.F. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995, 26:152-161.
110. Lee H.S., Lee J.S., Koh H.I., Ko K.W. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991, 36:67-75.
111. Proctor G., Jiang T., Iwahashi M., Wang Z., Li J., Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006, 55:2502-2509.
112. Sun L., Halaihel N., Zhang W., Rogers T., Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002, 277:18919-18927.
113. Wang Z., Jiang T., Li J., Proctor G., McManaman J.L., Lucia S., et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005, 54:2328-2335.
114. Bobulescu I.A. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010, 19:393-402.
115. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
116. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
117. Smulders Y.M., van Eeden A.E., Stehouwer C.D., Weijers R.N., Slaats E.H., Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?. Eur J Clin Invest 1997, 27:997-1002.
118. Obara K., Saito T., Sato H., Ogawa M., Igarashi Y., Yoshinaga K. Renal histology in two adult patients with type I glycogen storage disease. Clin Nephrol 1993, 39:59-64.
119. Detournay B, Simon D, Guillausseau PJ, Joly D, Verges B, Attali C, et al. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 38:102-12.
120. Faivre L., Houssin D., Valayer J., Brouard J., Hadchouel M., Bernard O. Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia. J Inherit Metab Dis 1999, 22:723-732.
121. Iyer S.G., Chen C.L., Wang C.C., Wang S.H., Concejero A.M., Liu Y.W., et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl 2007, 13:848-852.
122. Matern D., Starzl T.E., Arnaout W., Barnard J., Bynon J.S., Dhawan A., et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999, 158(Suppl 2):S43-S48.
123. Emmett M., Narins R.G. Renal tranplantation in type 1 glycogenosis. Failure to improve glucose metabolism. JAMA 1978, 239:1642-1644.
124. Pillot B., Soty M., Gautier-Stein A., Zitoun C., Mithieux G. Protein feeding promotes redistribution of endogenous glucose production to the kidney and potentiates its suppression by insulin. Endocrinology 2009, 150:616-624.
125. Mithieux G., Guignot L., Bordet J.C., Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 2002, 51:139-143.
126. Habegger K.M., Stemmer K., Cheng C., Muller T.D., Heppner K.M., Ottaway N., et al. Fibroblast growth Factor21 mediates specific glucagon actions. Diabetes 2013, 10.2337/db12-116.